New drug combo aims to protect transplanted hearts
NCT ID NCT03292861
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding Thymoglobulin to standard anti-rejection drugs helps prevent complications after a first heart transplant. About 60 adults will receive either standard therapy alone or standard therapy plus five days of Thymoglobulin. Researchers will check for signs of rejection and artery disease over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Thymoglobulin (an anti-rejection drug given intravenously)
What this could lead to
If it works, this could reduce the risk of heart transplant rejection and artery damage, helping transplanted hearts last longer.
What could go wrong
This is a small, early-phase study at one center, so results may not apply widely. Thymoglobulin can cause serious side effects like infections or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027, United States